Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1998 2
2001 1
2005 1
2006 1
2007 1
2008 2
2009 2
2010 3
2016 1
2018 1
2019 2
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

20 results
Results by year
Filters applied: . Clear all
Page 1
Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, Mistry PK. Murugesan V, et al. Among authors: kacena k. Am J Hematol. 2016 Nov;91(11):1082-1089. doi: 10.1002/ajh.24491. Epub 2016 Aug 8. Am J Hematol. 2016. PMID: 27441734 Free PMC article.
Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.
Blumberg LJ, Humphries JE, Jones SD, Pearce LB, Holgate R, Hearn A, Cheung J, Mahmood A, Del Tito B, Graydon JS, Stolz LE, Bitonti A, Purohit S, de Graaf D, Kacena K, Andersen JT, Christianson GJ, Roopenian DC, Hubbard JJ, Gandhi AK, Lasseter K, Pyzik M, Blumberg RS. Blumberg LJ, et al. Among authors: kacena k. Sci Adv. 2019 Dec 18;5(12):eaax9586. doi: 10.1126/sciadv.aax9586. eCollection 2019 Dec. Sci Adv. 2019. PMID: 31897428 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforêt P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT; NEO1 Investigator Group. Pena LDM, et al. Among authors: kacena k. Neuromuscul Disord. 2019 Mar;29(3):167-186. doi: 10.1016/j.nmd.2018.12.004. Epub 2018 Dec 17. Neuromuscul Disord. 2019. PMID: 30770310 Free article. Clinical Trial.
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, LaFrance N, Pauwels SA. Bushnell DL Jr, et al. Among authors: kacena ka. J Clin Oncol. 2010 Apr 1;28(10):1652-9. doi: 10.1200/JCO.2009.22.8585. Epub 2010 Mar 1. J Clin Oncol. 2010. PMID: 20194865 Free PMC article. Clinical Trial.
The risk of Parkinson's disease in type 1 Gaucher disease.
Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry PK. Bultron G, et al. Among authors: kacena k. J Inherit Metab Dis. 2010 Apr;33(2):167-73. doi: 10.1007/s10545-010-9055-0. Epub 2010 Feb 23. J Inherit Metab Dis. 2010. PMID: 20177787 Free PMC article.
Life expectancy in Gaucher disease type 1.
Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, vom Dahl S. Weinreb NJ, et al. Among authors: kacena ka. Am J Hematol. 2008 Dec;83(12):896-900. doi: 10.1002/ajh.21305. Am J Hematol. 2008. PMID: 18980271 Free PMC article.
Iodofiltic acid I 123 (BMIPP) fatty acid imaging improves initial diagnosis in emergency department patients with suspected acute coronary syndromes: a multicenter trial.
Kontos MC, Dilsizian V, Weiland F, DePuey G, Mahmarian JJ, Iskandrian AE, Bateman TM, Heller GV, Ananthasubramaniam K, Li Y, Goldman JL, Armor T, Kacena KA, LaFrance ND, Garcia EV, Babich JW, Udelson JE. Kontos MC, et al. Among authors: kacena ka. J Am Coll Cardiol. 2010 Jul 20;56(4):290-9. doi: 10.1016/j.jacc.2010.03.045. J Am Coll Cardiol. 2010. PMID: 20633821 Free article. Clinical Trial.
20 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page